Scancell Holdings plc – LSE:SCLP.L

Scancell Holdings stock price today

GBP 20
+9
+81.82%
Financial Health
0
1
2
3
4
5
6
7
8
9

Scancell Holdings stock price monthly change

-1.08%
month

Scancell Holdings stock price quarterly change

-1.08%
quarter

Scancell Holdings key metrics

Market Cap
 114.04M
Enterprise value
 7.09B
P/E
 -17
EV/Sales
 N/A
EV/EBITDA
 -1054.33
Price/Sales
 N/A
Price/Book
 4.35
PEG ratio
 -0.18
EPS
 -0.03
Revenue
 N/A
EBITDA
 -25.26M
Income
 -26.10M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Scancell Holdings stock price history

Scancell Holdings stock forecast

Scancell Holdings financial statements

Profit Margin

Scancell Holdings plc (LSE:SCLP.L): Profit margin
Apr 2021 0 -11.62M
Oct 2022 0 -3.16M
Apr 2023 5.27M -8.77M -166.38%
Oct 2023 0 -2.54M
SCLP.L income statement history

Scancell Holdings Financials Estimate

Scancell Holdings plc (LSE:SCLP.L): Analyst Estimates
2026 5.27M -14.8M -280.78%

  • Analysts Price target

  • Financials & Ratios estimates

Show more

Debt to Assets

Scancell Holdings plc (LSE:SCLP.L): Debt to assets
Oct 2020 31836000 7.11M 22.36%
Apr 2021 49058000 29.57M 60.28%
Oct 2022 44701000 22.00M 49.24%
Oct 2023 22252000 30.61M 137.58%
SCLP.L balance sheet history

Cash Flow

Scancell Holdings plc (LSE:SCLP.L): Cash Flow
Oct 2021 -4.62M -774K -140K
Oct 2022 -4.33M -149K -205K
Apr 2023 -4.05M -54K -4K
Oct 2023 -6.65M -13K -175K
SCLP.L cash flow history

Scancell Holdings alternative data

Scancell Holdings
Employees

Scancell Holdings plc (LSE:SCLP.L): Employee count
Aug 2023 40
Sep 2023 40
Oct 2023 40
Nov 2023 40
Dec 2023 51
Jan 2024 51
Feb 2024 51
Mar 2024 51
Apr 2024 51
May 2024 51
Jun 2024 51
Jul 2024 51

Scancell Holdings other data

Scancell Holdings
Executives

Insider Compensation
Dr. Sally Elizabeth Adams (1961) Chief Devel. Officer & Director
 $258,290

Frequently Asked Questions (FAQ)

  • What's the price of Scancell Holdings stock today?

    One share of Scancell Holdings stock can currently be purchased for approximately $20.

  • When is Scancell Holdings's next earnings date?

    Scancell Holdings plc is estimated to report earnings on Monday, 22 Sep 2025.

  • Does Scancell Holdings pay dividends?

    No, Scancell Holdings does not pay dividends.

  • How much money does Scancell Holdings make?

    Scancell Holdings has a market capitalization of 114.04M.

  • What is Scancell Holdings's stock symbol?

    Scancell Holdings plc is traded on the LSE under the ticker symbol "SCLP.L".

  • What is Scancell Holdings's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Scancell Holdings?

    Shares of Scancell Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Scancell Holdings's key executives?

    Scancell Holdings's management team includes the following people:

    • Dr. Sally Elizabeth Adams Chief Devel. Officer & Director(age: 64, pay: $258,290)

  • How many employees does Scancell Holdings have?

    As Jul 2024, Scancell Holdings employs 51 workers.

  • When Scancell Holdings went public?

    Scancell Holdings plc is publicly traded company for more then 15 years since IPO on 12 Feb 2010.

  • What is Scancell Holdings's official website?

    The official website for Scancell Holdings is scancell.co.uk.

  • How can i contact Scancell Holdings?

    Scancell Holdings can be reached via phone at +44 1865 582066.

Scancell Holdings company profile:

Scancell Holdings plc

scancell.co.uk
Exchange:

LSE

Full time employees:

61

Industry:

Biotechnology

Sector:

Healthcare

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

+44 1865 582066
Unit 202 Bellhouse Building
Oxford, OX4 4GD

:
ISIN: GB00B63D3314
CUSIP: G7856P123